Health policy: Me-too drugs with limited benefits-the tale of regorafenib for HCC

Bishal Gyawali; Vinay Prasad

doi:10.1038/nrclinonc.2017.100

Health policy: Me-too drugs with limited benefits-the tale of regorafenib for HCC

Bishal Gyawali, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Short survey › peer-review

19 Scopus citations

Original language	English (US)
Pages (from-to)	653-654
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	14
Issue number	11
DOIs	https://doi.org/10.1038/nrclinonc.2017.100
State	Published - Nov 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2017.100

Cite this

@article{17df9063329946268231f1180e0ee944,

title = "Health policy: Me-too drugs with limited benefits-the tale of regorafenib for HCC",

author = "Bishal Gyawali and Vinay Prasad",

note = "Funding Information: The work of V.P. is funded by the Laura and John Arnold Foundation to study low-value practices.",

year = "2017",

month = nov,

day = "1",

doi = "10.1038/nrclinonc.2017.100",

language = "English (US)",

volume = "14",

pages = "653--654",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Health policy

T2 - Me-too drugs with limited benefits-the tale of regorafenib for HCC

AU - Gyawali, Bishal

AU - Prasad, Vinay

N1 - Funding Information: The work of V.P. is funded by the Laura and John Arnold Foundation to study low-value practices.

PY - 2017/11/1

Y1 - 2017/11/1

UR - http://www.scopus.com/inward/record.url?scp=85030868808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030868808&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2017.100

DO - 10.1038/nrclinonc.2017.100

M3 - Short survey

C2 - 28719584

AN - SCOPUS:85030868808

SN - 1759-4774

VL - 14

SP - 653

EP - 654

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 11

ER -

Health policy: Me-too drugs with limited benefits-the tale of regorafenib for HCC

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this